Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder

Summary

The HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo. The first 50 participants will have functional brain scans (fMRI) to investigate how the brain responds to cannabis-related cues. The main outcome after 20 weeks is whether semaglutide reduces cannabis use compared to placebo. Changes in brain activity in response to cannabis cues will be explored as a secondary outcome.

Timeline

Start

2026-04-30

Primary completion

2028-04-30

Completion

2028-04-30

Drugs

Indications